Aripiprazole/Escitalopram

阿立哌唑/右旋西酞普兰

Report date: 2023/09/15 16:16:28

Base Information

Drug NameAripiprazole/Escitalopram
Drug Alias NameOPC-14597/escitalopram右旋西酞普兰/阿立哌唑右旋西酞普兰+阿立哌唑OPC-14597+escitalopram阿立哌唑+右旋西酞普兰 +[8] 
ClassificationSmall molecules
Mechanisms of ActionDopamine D3 receptor agonistsSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor agonists +[5] 
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor +[5] 
Therapy Area/IndicationsDepressive Disorder, Major
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes AripiprazoleEscitalopram Oxalate
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOtsuka Holdings Co Ltd
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, Major

Other Information

ATC CodeN/A
Related LinksN/A